Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM49DUI)

Drug Name
Tretinoin Drug Info
Synonyms
Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid
Therapeutic ClassKeratolytic Agents
Cross-matching ID
PubChem CID
444795
ChEBI ID
CHEMBL15367
CAS Number
CAS 302-79-4
TTD Drug ID
D02DGU
VARIDT Drug ID
DR00154
INTEDE Drug ID
DR1634
ACDINA Drug ID
D00699

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.20 7.89e-3 34/36 (94.44%) RFC2;MCM3;POLE2;...
IL-17 signaling pathway 2.12 3.94e-3 84/94 (89.36%) CXCL8;CCL2;FOSL1;...
Legionellosis 2.08 2.63e-3 51/57 (89.47%) CXCL8;CXCL1;HSPA6;...
Spliceosome 2.08 1.97e-3 101/150 (67.33%) HSPA6;SNRNP40;SNRPF;...
Ribosome biogenesis in eukaryotes 2.00 3.15e-3 52/108 (48.15%) NOP56;NXT1;IMP3;...
TNF signaling pathway 1.95 3.94e-3 103/112 (91.96%) CCL2;CXCL1;CXCL6;...
Viral protein interaction with cytokine and cytokine re... 1.93 4.51e-3 84/100 (84%) CXCL8;CCL2;CXCL1;...
Cytosolic DNA-sensing pathway 1.92 3.94e-3 52/63 (82.54%) CCL5;IL1B;POLR3K;...
Proteasome 1.91 4.38e-3 44/46 (95.65%) PSMA3;PSME3;PSMB10;...
Retinol metabolism 1.91 3.94e-3 41/68 (60.29%) ALDH1A3;DHRS3;ALDH1A1;...
Malaria 1.90 5.02e-3 44/50 (88%) CXCL8;CCL2;VCAM1;...
Pertussis 1.88 5.26e-3 64/76 (84.21%) CXCL8;CXCL6;CXCL5;...
RNA transport 1.85 8.49e-3 128/186 (68.82%) EIF5;GEMIN4;NXT1;...
Glutathione metabolism 1.85 7.89e-3 43/57 (75.44%) GPX2;GCLM;PGD;...
Toll-like receptor signaling pathway 1.82 8.94e-3 94/104 (90.38%) CXCL8;CCL5;FADD;...
Mismatch repair 1.82 8.38e-3 22/23 (95.65%) RFC2;RPA2;EXO1;...
Pyrimidine metabolism 1.82 7.89e-3 40/56 (71.43%) UPP1;CTPS1;UMPS;...
Folate biosynthesis 1.78 1.36e-2 23/26 (88.46%) AKR1B10;AKR1C3;AKR1B1;...
Fanconi anemia pathway 1.76 1.49e-2 36/54 (66.67%) HES1;BLM;RAD51;...
Base excision repair 1.76 1.46e-2 29/33 (87.88%) POLE2;NEIL3;PARP4;...
Pentose phosphate pathway 1.74 1.46e-2 25/30 (83.33%) PGD;RPIA;TKT;...
NF-kappa B signaling pathway 1.74 1.43e-2 90/104 (86.54%) CXCL8;CXCL1;VCAM1;...
Chagas disease 1.72 1.61e-2 93/102 (91.18%) CXCL8;CCL2;CCL5;...
Influenza A 1.72 1.54e-2 156/172 (90.7%) CXCL8;CCL2;DNAJB1;...
RNA polymerase 1.70 1.77e-2 23/31 (74.19%) POLR3K;POLR1C;POLR2D;...
Yersinia infection 1.69 1.85e-2 120/137 (87.59%) CXCL8;CCL2;SKAP2;...
Ribosome 1.67 2.28e-2 113/158 (71.52%) MRPS12;MRPL24;MRPL12;...
Ubiquinone and other terpenoid-quinone biosynthesis 1.66 2.39e-2 9/11 (81.82%) NQO1;GGCX;COQ2
Coronavirus disease 1.65 2.39e-2 215/232 (92.67%) CXCL8;CCL2;TNFRSF1A;...
Ferroptosis 1.63 2.97e-2 36/41 (87.8%) HMOX1;GCLM;ACSL5;...
Renin-angiotensin system -1.64 4.93e-2 20/23 (86.96%) AGTR2;KLK1;CMA1;...
Endometrial cancer -1.67 4.60e-2 56/58 (96.55%) AKT3;TCF7;MAP2K2;...
PPAR signaling pathway -1.67 4.45e-2 66/74 (89.19%) FABP7;SORBS1;PLIN1;...
Arginine and proline metabolism -1.69 4.60e-2 39/50 (78%) ALDH4A1;LAP3;AOC1;...
Terpenoid backbone biosynthesis -1.74 3.59e-2 18/22 (81.82%) MVK;GGPS1;ACAT2;...
Valine, leucine and isoleucine degradation -1.75 3.68e-2 42/48 (87.5%) ALDH7A1;ACAD8;MCCC1;...
Arrhythmogenic right ventricular cardiomyopathy -1.75 3.80e-2 70/77 (90.91%) ITGA10;CACNB4;LAMA1;...
Arginine biosynthesis -1.76 3.78e-2 17/22 (77.27%) GLS;GOT1;CPS1;...
Synaptic vesicle cycle -1.78 3.38e-2 63/78 (80.77%) ATP6V0C;STX2;SLC6A9;...
Proximal tubule bicarbonate reclamation -1.80 2.85e-2 21/23 (91.3%) GLS;FXYD2;MDH1;...
ECM-receptor interaction -1.81 3.15e-2 80/88 (90.91%) COMP;RELN;TNXB;...
Biosynthesis of unsaturated fatty acids -1.84 1.97e-2 21/27 (77.78%) ACAA1;HSD17B4;ACOT7;...
Fatty acid elongation -1.89 1.31e-2 19/27 (70.37%) ACOT7;HSD17B12;HACD2;...
Steroid biosynthesis -2.14 0.00e+0 19/20 (95%) HSD17B7;FDFT1;SC5D;...
Protein digestion and absorption -2.36 0.00e+0 78/103 (75.73%) COL7A1;KCNQ1;COL4A4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 40uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 20uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 40uM 6H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 12uM - 100uM 48H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 40uM 6H
HT-29 CVCL_0320 Homo sapiens 0.04uM - 40uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 40uM 6H
MDST8 CVCL_1400 Homo sapiens 40uM 6H
NCI-H508 CVCL_1561 Homo sapiens 40uM 6H
SNU-1040 CVCL_5001 Homo sapiens 40uM 6H
SNU-C4 CVCL_5008 Homo sapiens 40uM 6H
SNU-C5 CVCL_5009 Homo sapiens 40uM 6H
SW480 CVCL_0546 Homo sapiens 40uM 6H
SW620 CVCL_0547 Homo sapiens 40uM 6H
SW948 CVCL_0550 Homo sapiens 40uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 40uM 6H
RKO CVCL_0504 Homo sapiens 40uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 40uM 6H
SNG-M CVCL_1707 Homo sapiens 40uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 40uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 40uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 100uM 3H, 6H, 24H, 48H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 40uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 40uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 40uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 40uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 40uM 6H
T3M-10 CVCL_1729 Homo sapiens 40uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 40uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 40uM 6H
HCC515 CVCL_5134 Homo sapiens 0.04uM - 40uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 40uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 40uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 40uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 40uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 40uM 6H
OV7 CVCL_1623 Homo sapiens 40uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 40uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 40uM 6H
RMUG-S CVCL_1666 Homo sapiens 40uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 40uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 3.33uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 40uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HL-60 CVCL_0002 Homo sapiens 0.37uM - 10uM 6H, 24H
PL-21 CVCL_2161 Homo sapiens 40uM 6H
SKM-1 CVCL_0010 Homo sapiens 40uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 0.37uM - 40uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 40uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 1.11uM - 40uM 6H, 24H, 48H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 40uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 40uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 40uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 40uM 6H